La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !
Amgen Gestione
Gestione criteri di controllo 3/4
Amgen's Il CEO è Bob Bradway, nominato in May2010, e ha un mandato di 14.25 anni. la retribuzione annua totale è $ 22.64M, composta da 7.9% di stipendio e 92.1% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.12% delle azioni della società, per un valore di $ 206.50M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 4.9 anni e 7.7 anni.
Informazioni chiave
Bob Bradway
Amministratore delegato
US$22.6m
Compenso totale
| Percentuale dello stipendio del CEO | 7.9% |
| Mandato del CEO | 14.3yrs |
| Proprietà del CEO | 0.1% |
| Durata media del management | 4.7yrs |
| Durata media del Consiglio di amministrazione | 7.8yrs |
Aggiornamenti recenti sulla gestione
Recent updates
Amgen: Pipeline Updates, Uplizna Performs And Rocatinlimab Underwhelms
Sep 26Amgen: Growth Is Still A Better Choice
Aug 28Amgen Inc. Just Missed EPS By 46%: Here's What Analysts Think Will Happen Next
Aug 09
Amgen: Shows Why Dividend Investing Is Getting Tougher
Aug 07Amgen (NASDAQ:AMGN) Takes On Some Risk With Its Use Of Debt
Jul 26The Price Is Right For Amgen Inc. (NASDAQ:AMGN)
Jul 11Amgen: An Emerging GLP-1 Play, Modest Mid-Teens P/E With Strong Momentum
Jul 05Amgen: You Haven't Seen Anything Yet
Jun 17Amgen Is A Fantastic Dividend Growth Stock With A Weight-Loss Wild Card
Jun 04Amgen Stock: Poised To Break Out (Technical Analysis)
May 21Is Amgen Inc. (NASDAQ:AMGN) Trading At A 41% Discount?
May 04Amgen Stock: Recent Weakness Is Not A Buying Opportunity Yet
May 01Amgen: The Giant With An Impressive Pipeline
Apr 15Is Amgen (NASDAQ:AMGN) Using Too Much Debt?
Apr 01Move Over Eli Lilly: Amgen Could Be The Next Obesity Wonder Stock
Mar 31Amgen Will Benefit From Increased Medical Spending
Mar 12Amgen: A Good Dividend Growth Stock For The Watch List
Mar 04Amgen's (NASDAQ:AMGN) Shareholders May Want To Dig Deeper Than Statutory Profit
Feb 21Pinning Down Amgen Inc.'s (NASDAQ:AMGN) P/E Is Difficult Right Now
Feb 16Amgen: Weight Loss Drug Candidate Debate A Red Herring - Buying The Dip Advisable
Feb 08Amgen: Accelerating The Business And Dividend Growth
Jan 29Is Amgen Inc. (NASDAQ:AMGN) Trading At A 44% Discount?
Jan 29Up 40%, 3%-Yielding Amgen Is Still One Of My Favorite Healthcare Stocks
Jan 22Is Amgen (NASDAQ:AMGN) A Risky Investment?
Dec 28Here's Why Amgen (NASDAQ:AMGN) Has Caught The Eye Of Investors
Dec 13Are Investors Undervaluing Amgen Inc. (NASDAQ:AMGN) By 46%?
Oct 23Is Amgen (NASDAQ:AMGN) Using Too Much Debt?
Sep 22Do Amgen's (NASDAQ:AMGN) Earnings Warrant Your Attention?
Sep 04Amgen (NASDAQ:AMGN) Is Increasing Its Dividend To $2.13
Aug 05Analisi delle retribuzioni degli amministratori delegati
| Data | Compenso totale | Stipendio | Guadagni aziendali |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | US$3b |
| Mar 31 2024 | n/a | n/a | US$4b |
| Dec 31 2023 | US$23m | US$2m | US$7b |
| Sep 30 2023 | n/a | n/a | US$8b |
| Jun 30 2023 | n/a | n/a | US$8b |
| Mar 31 2023 | n/a | n/a | US$8b |
| Dec 31 2022 | US$21m | US$2m | US$7b |
| Sep 30 2022 | n/a | n/a | US$7b |
| Jun 30 2022 | n/a | n/a | US$7b |
| Mar 31 2022 | n/a | n/a | US$6b |
| Dec 31 2021 | US$22m | US$2m | US$6b |
| Sep 30 2021 | n/a | n/a | US$6b |
| Jun 30 2021 | n/a | n/a | US$6b |
| Mar 31 2021 | n/a | n/a | US$7b |
| Dec 31 2020 | US$20m | US$2m | US$7b |
| Sep 30 2020 | n/a | n/a | US$7b |
| Jun 30 2020 | n/a | n/a | US$7b |
| Mar 31 2020 | n/a | n/a | US$8b |
| Dec 31 2019 | US$20m | US$2m | US$8b |
| Sep 30 2019 | n/a | n/a | US$8b |
| Jun 30 2019 | n/a | n/a | US$8b |
| Mar 31 2019 | n/a | n/a | US$8b |
| Dec 31 2018 | US$19m | US$2m | US$8b |
| Sep 30 2018 | n/a | n/a | US$2b |
| Jun 30 2018 | n/a | n/a | US$2b |
| Mar 31 2018 | n/a | n/a | US$2b |
| Dec 31 2017 | US$17m | US$2m | US$2b |
Compensazione vs Mercato: La retribuzione totale di Bob ($USD 22.64M ) è superiore alla media delle aziende di dimensioni simili nel mercato US ($USD 13.17M ).
Compensazione vs guadagni: La retribuzione di Bob è stata coerente con le performance aziendali dell'ultimo anno.
AMMINISTRATORE DELEGATO
Bob Bradway (61 yo)
14.3yrs
Mandato
US$22,643,650
Compensazione
Mr. Robert A. Bradway, also known as Bob, has been the Chief Executive Officer of Amgen Inc. since May 23, 2012 and has been its President since May 2010. Mr. Bradway is responsible for the Amgen's global...
Gruppo dirigente
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| Chairman | 14.3yrs | US$22.64m | 0.12% $ 202.8m | |
| Executive VP & CFO | 4.7yrs | US$7.57m | 0.0046% $ 8.0m | |
| Executive Vice President of Operations | 8.2yrs | US$7.21m | 0.011% $ 19.8m | |
| Executive VP & CTO | less than a year | US$7.90m | 0.0094% $ 16.3m | |
| Executive Vice President of Global Commercial Operations | 6yrs | US$8.24m | 0.0075% $ 12.9m | |
| Chief Accounting Officer & VP of Finance | 1.1yrs | Nessun dato | 0.00056% $ 970.9k | |
| Executive VP of Research & Development and Chief Scientific Officer | less than a year | Nessun dato | Nessun dato | |
| Vice President of Investor Relations | no data | Nessun dato | Nessun dato | |
| Executive VP | 9.2yrs | US$7.24m | 0.0046% $ 8.1m | |
| Senior VP of Worldwide Compliance & Business Ethics and Chief Compliance Officer | 4.7yrs | Nessun dato | 0.0013% $ 2.3m | |
| Senior Vice President of Global Marketing & Access | less than a year | Nessun dato | Nessun dato | |
| Senior Vice President of Human Resources | 2.7yrs | Nessun dato | 0.0012% $ 2.0m |
4.7yrs
Durata media
56.5yo
Età media
Gestione esperta: Il team dirigenziale di AMGN è considerato esperto (durata media dell'incarico 4.9 anni).
Membri del Consiglio di amministrazione
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| Chairman | 12.9yrs | US$22.64m | 0.12% $ 202.8m | |
| Lead Independent Director | 11.8yrs | US$419.92k | 0.0013% $ 2.3m | |
| Co-Chair of Scientific Advisory Board | no data | US$292.01k | Nessun dato | |
| Co-Chair of the Scientific Advisory Board | no data | Nessun dato | Nessun dato | |
| Independent Director | 4.2yrs | US$359.92k | 0.000080% $ 138.7k | |
| Independent Director | 7.6yrs | US$369.92k | 0.00023% $ 398.8k | |
| Independent Director | 10.9yrs | US$379.92k | 0.0023% $ 4.0m | |
| Independent Director | 7.9yrs | US$360.29k | 0.000080% $ 138.7k | |
| Independent Director | 6.3yrs | US$359.92k | 0.00015% $ 260.1k | |
| Independent Director | 12.3yrs | US$339.92k | 0.00051% $ 884.2k | |
| Independent Director | 6.8yrs | US$359.92k | 0.0012% $ 2.1m | |
| Independent Director | 3.2yrs | US$366.47k | 0.00017% $ 294.7k |
7.8yrs
Durata media
68yo
Età media
Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di AMGN sono considerati esperti (durata media dell'incarico 7.7 anni).